HYP-DMD-01

HYP-DMD-01 is an investigational allogeneic cell therapy composed of mesenchymal stem cells (MSCs) derived from the umbilical cord lining (ULSCs). Developed by RESTEM LLC in collaboration with the University of Florida College of Medicine, the therapy is currently in Phase 1 clinical development for the treatment of Duchenne Muscular Dystrophy (DMD). The mechanism of action involves the systemic administration of these stem cells, which are hypothesized to migrate to damaged muscle tissue and exert immunomodulatory and regenerative effects. By secreting various trophic factors and cytokines, the cells aim to reduce chronic inflammation, decrease muscle fibrosis, and promote the repair of dystrophic muscle fibers, potentially slowing the progression of the disease and improving muscle function. The program is supported by the philanthropic organization JAR of Hope.

Other names

Umbilical Cord Lining Stem CellsULSCRESTEM cell therapy